Фармкомпании смещают фокус с общего снижения веса на состав тела, целясь в сохранение мышц и снижение жира как следующую границу в лечении ожирения. На медицинской конференции в Милане исследования средней и поздней стадии от Novo, Eli Lilly и Regeneron показали, что несколько кандидатов лекарств могут лучше сохранять мышцы, помогая при этом сжигать проблемный жир на животе. Часто Rapid weight loss comes with the downside of losing significant muscle, which can increase the risk of falls and injuries. Regeneron reported mid-stage data showing patients lost about two-thirds to three-quarters less thigh muscle than those taking semaglutide alone. Over 26 weeks, highest doses roughly halved the loss of lean mass compared to those on semaglutide.
Eli Lilly researcher Dr. Juan Pablo Frías emphasized the goal is retaining muscle so patients can maintain mobility, stating, "I’d rather have more fat loss and slightly less weight loss, but retain more muscle. I want you to be able to bend down and tie your shoe without difficulty." Novo presented data on Cagri Sema, showing Type 2 diabetes patients lost 14.3% of body weight over nine months and had less fat around the liver and pancreas. International patent applications for GLP-1s rose 28% in the 12 months to March 2026, highlighting the increasingly competitive landscape as companies differentiate their next-generation pipelines.
Источник: Wall Street Journal US Business · Сводку подготовил HeadlinesBriefing